Evolving determinants of carotid atherosclerosis vulnerability in asymptomatic patients from the MAGNETIC observational study

Oronzo Catalano1, Giulia Bendotti1, Alessia Mori1, Maria De Salvo1, Marialuisa Falconi2, Teresa L. Alo2, Valentina Tibollo1, Riccardo Bellazzi4, Alberto Ferrari Bardile2, Stefano Montagna5, Clara Pesarin5, Paolo Poggi5, Roberto F. E. Pedretti1 & Silvia G. Priori6,7

MRI can assess plaque composition and has demonstrated an association between some atherosclerotic risk factors (RF) and markers of plaque vulnerability in naive patients. We aimed at investigating this association in medically treated asymptomatic patients. This is a cross-sectional interim analysis (August 2013–September 2016) of a single center prospective study on carotid plaque vulnerability (MAGNETIC study). We recruited patients with asymptomatic carotid atherosclerosis (US stenosis > 30%, ECST criteria), receiving medical treatments at a tertiary cardiac rehabilitation. Atherosclerotic burden and plaque composition were quantified with 3.0 T MRI. The association between baseline characteristics and extent of lipid-rich necrotic core (LRNC), fibrous cap (CAP) and intraplaque hemorrhage (IPH) was studied with multiple regression analysis. We enrolled 260 patients (198 male, 76%) with median age of 71-y (interquartile range: 65–76). Patients were on antiplatelet therapy, ACE-inhibitors/angiotensin receptor blockers and statins (196–229, 75–88%). Median LDL-cholesterol was 78 mg/dl (59–106), blood pressure 130/70 mmHg (111–140/65–80), glycosylated hemoglobin 46 mmol/mol (39–51) and BMI 25 kg/m² (23–28); moreover, 125 out of 187 (67%) patients were ex-smokers. Multivariate analysis of a data-set of 487 (94%) carotid arteries showed that a history of hypercholesterolemia, diabetes, hypertension or smoking did not correlate with LRNC, CAP or IPH. Conversely, maximum stenosis was the strongest independent predictor of LRNC, CAP and IPH (p < 0.001). MRI assessment of plaque composition in patients on treatment for asymptomatic carotid atherosclerosis shows no correlation between plaque vulnerability and the most well-controlled modifiable RF. Conversely, maximum stenosis exhibits a strong correlation with vulnerable features despite treatment.

Magnetic resonance imaging (MRI) provides a means to non-invasively assess luminal narrowing and composition of atherosclerotic carotid plaques. Many studies have correlated MRI findings with histology of excised carotid plaques, demonstrating that MRI can accurately assess lipid-rich necrotic core (LRNC), fibrous cap (CAP), intraplaque hemorrhage (IPH), calcification (CA) and plaque surface abnormalities1–9. Retrospective and prospective studies have shown an association between carotid plaques assessed by MRI and cerebral ischemic events10–13. Recently, observational studies have assessed carotid atherosclerosis features in asymptomatic and symptomatic patients and their correlations with risk factors (RF) for atherosclerosis14–16. In asymptomatic patients with carotid plaques, IPH and LRNC, two indexes of plaque vulnerability are highly frequent, occurring in about 25% of plaques and in about 75% of patients assessed with MRI14.
The MAGNETIC (Magnetic resonance imaging As a Gold standard for Noninvasive Evaluation of a Thoro
cortic Involvement of Carotid arteries) study is an observational prospective study, on natural history of
vulnerable carotid plaques, in a cohort of patients with asymptomatic mild to moderate carotid atherosclerosis,
medically treated in a tertiary rehabilitation setting. Using serial multi-contrast MRI and a quantitative analysis
of MRI images, the study is testing the hypothesis of the potential reversibility of plaque vulnerability features.
The present work assessed the MAGNETIC study population characteristics at the baseline, with focus on plaque
composition and atherosclerotic burden in order to confirm the correlation between RF and vulnerable plaque
components.

Results
The study enrolled 260 Caucasian patients from August 2013 to September 2016 (baseline characteristics are
summarized in Table 1). Fourteen patients were excluded from the analysis due to poor image quality. Moreover,
in five patients one carotid axis was excluded because of poor image quality, a high bifurcation position or
excessive vessel angulation. In this interim analysis of baseline assessment, a dataset of 487 (94%) carotid arteries
with adequate image quality was analyzed.

Two hundred twenty-nine patients (88%) were on aspirin/antiplatelet therapy, 197 (76%) on ACE-inhibitors/
angiotensin receptor blocker and 196 (75%) on statins. Baseline median LDL cholesterol was 78 mg/dl (59–106),
blood pressure 130/70 mmHg (111–140/65–80), glycosylated hemoglobin 46 mmol/mol (39–51) and BMI 25
(23–28).

Maximum stenosis was less than 50%, between 50 and 70% and more than 70% respectively in 19%, 67% and
14% of assessable carotid axes.

Determinants of vulnerable plaque: univariate analysis. Univariate analysis did not show a significant
association between most modifiable RF and components linked to plaque vulnerability. Indeed, no correlation
of LRNC, CAP and IPH with a history of hypercholesterolemia, diabetes, hypertension and smoke, or with
RF burden (total number of RF) was found, with the exception of a weak association of LRNC with RF burden
(Spearman’s ρ = 0.09, p = 0.038). Moreover, there was no correlation between a composite score of baseline RF
level and plaque vulnerability.

Carotid atherosclerosis metrics were linked to changes in atherosclerotic plaque composition. In fact, a
moderate correlation was found between peak stenosis and LRNC, CAP and IPH (p between 0.35 and 0.53;
p < 0.001). Similar results were found considering atherosclerotic burden (p between 0.31 and 0.42; p < 0.001).

Male sex was mildly correlated with LRNC (Mann–Whitney test, p = 0.007), CAP (p = 0.001) and IPH
(p = 0.017), although men and women showed an identical burden of atherosclerotic RF (three [range: two to
three] vs three [range: two to three]: p = 0.406). Men had higher carotid lumen volume (920 mm³ [745–1096] vs
774 mm³ [608–971]; p < 0.001) and maximum area (48 mm² [40–60] vs 38 mm² [31–52]; p < 0.001).

There was a marginal correlation between age and LRNC (p = 0.10, p = 0.022) but not between age and CAP
or IPH.

CAD comorbidity was mildly linked with LRNC (p < 0.001), CAP (p = 0.004) and IPH (p < 0.001). Familial
history of premature CAD was mildly associated with LRNC (p = 0.008) as well.

PAD comorbidity was not associated with LRNC, CAP and IPH.

Because of the exclusion of severe/end stage chronic kidney disease (CKD), two-thirds of enrolled patients
showed normal or near-normal eGFR (CKD stage 1–2: n = 169, 65%), while one-third moderate renal impairment
(stage 3: n = 91, 35%). We found a mild inverse correlation between eGFR and LRNC (p = 0.13; p = 0.005) and
CAP (p = −0.10; p = 0.026) but no association between eGFR and IPH (p = −0.07; p = 0.099).

Left carotid side mildly correlated with LRNC (p = 0.013), CAP (p = 0.029) and IPH (p = 0.013).

The complete set of univariate correlations and a graphical display of univariate association between plaque
components (atherosclerotic burden) and key baseline population characteristics are shown in Supplemen-
tary Table S2 and Fig. 1, respectively.

Determinants of vulnerable plaque: multiple regression analysis. Multiple regression analysis
(Table 2) showed that maximum stenosis was the strongest independent factor correlated with plaque vulner-
ability (association with LRNC, CAP and IPH: p < 0.001). Moreover, there was an independent association of
features of plaque vulnerability with left side, male sex, familial history of premature CAD, coexisting CAD and
BMI.

Discussion
Modifiable risk factors and markers of plaque vulnerability. In recent years, MRI has widened and
improved assessment of atherosclerotic plaque composition, beyond other noninvasive imaging techniques like
ultrasound and computer tomography.

With MRI, it has been possible to demonstrate that plaque vulnerability characteristics are related to ather-
osclerotic RF. This was found in naive populations with asymptomatic carotid atherosclerosis. Van den Bouwhi-
sen et al. (the Rotterdam Study) showed a correlation between hypertension, current smoking and presence of
IPH, and between hypercholesterolemia and LRNC11. In other cohorts of asymptomatic patients, Wasserman
et al. (the MESA Study) and Virani et al. (the ARIC Study) showed that plasma LDL cholesterol and non-HDL
cholesterol are the most important determinants of LRNC15,16.

In the present study, a baseline interim analysis of MAGNETIC prospective observational study, we investi-
gated the persistence of a correlation between RF and plaque components in a cohort of asymptomatic subjects
followed at a tertiary rehabilitation facility and receiving evidence-based medical treatment. In this setting, we
found no association between MRI assessment of high-risk plaque features and a history of hypertension, diabetes mellitus, hypercholesterolemia and smoking, and only a mild association between BMI and intraplaque hemorrhage and lipid content. Thus, it seems that optimization of medical therapy and a healthier lifestyle might have blunted the association between modifiable RF and plaque vulnerability. These findings are consistent with recent results that showed, in biobanked carotid plaques, a significant decrease over time of large atheromas and an increase of plaques with fibrous non-inflammatory characteristics. Our observations are also consistent with the progressive decrease in stroke incidence, observed since the mid-1980s, in the medical arms of randomized trials comparing different treatment strategies for asymptomatic severe carotid atherosclerosis.

**Sex, familial predisposition and markers of plaque vulnerability.** We also investigated the association between plaque vulnerability and non-modifiable genetically determined or potentially transmissible char-

| Atherosclerosis risk factors | Median (interquartile range) | n (%) |
|-----------------------------|-------------------------------|-------|
| Familial history of premature CAD | 51 (20) |       |
| Smoke | 187 (72) |       |
| Active smoke | 62 (24) |       |
| Hypercholesterolemia | 168 (65) |       |
| Diabetes | 92 (35) |       |
| Hypertension | 207 (80) |       |
| Total # risk factors | 4 (3–4) |       |
| ≥ 3 RF | 212 (82) |       |
| BMI ≥ 30 kg/m² | 25 (23–28) |       |
| BMI ≥ 30 kg/m² | 30 (12) |       |

**Extra carotid atherosclerosis**
- Coronary artery disease: 171 (66)
- Peripheral arterial disease: 52 (20)

**Blood chemistry**
- LDL Cholesterol (mg/dl) 78 (59–106)
- LDL Chol. ≥ 70 mg/dl 157 (60)
- Triglycerides (mg/dl) 118 (92–169)
- Triglycerides ≥ 150 mg/dl 77 (30)
- HDL Cholesterol (mg/dl) 43 (33–52)
- HDL ≤ 35 mg/dl 80 (31)
- Glycosylated hemoglobin (mmol/mol) 43 (39–51)
- Glycosylate HB ≥ 54 mmol/mol 48 (18)
- HS C-Reactive protein (mg/dl) 0.36 (0.13–1.24)
- HS-CRP ≥ 3 mg/dl 38 (1.5)
- EGFR 68 (55–83)
- EGFR > 90, 60–89, < 60 41 (16), 128 (49), 91 (35)
- Arterial blood pressure
  - Systolic BP mmHg 130 (111–140)
  - SBP ≥ 140 mmHg 69 (27)
  - Diastolic BP mmHg 70 (65–80)
  - DBP ≥ 90 mmHg 6 (2)

**Medical therapy**
- Aspirin/antiplatelet 229 (88)
- ACE-inhibitors/ARB 197 (76)
- Statins 196 (75)

**Table 1.** Baseline characteristics of the study population (260 patients). CAD coronary artery disease, BMI body mass index, LDL low density lipoprotein, HDL high density lipoprotein, EGFR estimated glomerular filtration rate, BP blood pressure, ACE angiotensin converting enzyme.
characteristics, such as male sex and familial history of premature CAD. As the effect of sex is concerned, it is well known that stroke incidence and prevalence is higher in men than in women between the ages of 45 and 74.24 In addition, histological analysis of excised plaques25,26 and in vivo assessment with MRI14,27 have documented differences in plaque morphology in relation to sex. In agreement with these studies, we found that components associated with plaque vulnerability (IPH, LRNC and CAP) are quantitatively more represented in men than women.

Figure 1. Trends of atherosclerotic burden and vulnerable plaque components by modifiable risk factors, maximum stenosis, familial history of premature CAD, sex, age, renal function and carotid side (univariate analysis). NWI normalized wall index, CAD coronary artery disease, LRNC lipid-reach necrotic core, CAP fibrous cap, IPH intraplaque hemorrhage, RF risk factors, EGFR estimated glomerular filtration rate. Bars are the median value. Kruskal–Wallis test was used to test differences, with Bonferroni correction for multiple comparisons; ***p < 0.001; **p < 0.01; *p < 0.05.

Table 2. Final multiple regression models predicting vulnerable plaque components. This table shows only significant variables in the final model. The complete set of variables included in the analysis are reported in Supplementary Material. Fam. Hist. of CAD familial history of coronary artery disease.
in women. This finding has been assumed to be related to variability in cardiovascular RF, levels of hormones or carotid anatomy. In our cohort, atherosclerotic risk was globally balanced between the two sexes but men showed a larger lumen size than women. Thus, it might be hypothesized that hemodynamic and anatomic factors may be relevant for carotid plaque vulnerability in men. Notably, association between male sex and both LRNC and CAP remained unchanged after correction for all other significant factors.

As regards CAD comorbidity, it is known that the presence of carotid plaque predicts future CAD events, and that carotid and coronary vulnerable plaques share a similar pattern of disruption. The correlation between vulnerable plaque components and the presence of CAD in the index patient or even in a first-degree relative, found in the present study, seems to confirm a common substrate potentially able to trigger plaque vulnerability and, as a consequence, a coronary or a cerebral ischemic event. Multiple regression analysis showed that CAD comorbidity and familial history of premature CAD are independently associated with plaque vulnerability.

Carotid artery aging, atherosclerotic burden and plaque composition. Atherosclerosis may develop at an early age and increase with aging. In a cohort of subjects with asymptomatic carotid atherosclerosis, we observed that age correlates with carotid wall volume, maximum stenosis and atherosclerotic burden. However, we found only a mild association between age and LRNC content, and no association with other markers of plaque vulnerability, such as IPH. This is in contrast with previous studies. Significant lower blood pressure in our cohort might have blunted the confounding effect of this factor, known to be associated with both aging and IPH. Like aging, renal function impairment correlated with modifications of carotid wall, such as increase of wall volume and atherosclerotic burden, and with LRNC content. Neither age nor eGFR were found to be independently associated with plaque vulnerability in the present study.

Luminal stenosis, atherosclerotic burden and plaque composition. The degree of carotid luminal stenosis is one of the main criteria for identifying high-risk asymptomatic patients who could benefit from carotid endarterectomy. Studies from the 1980’s and 1990’s demonstrated an association of IPH and plaque ulceration with the degree of stenosis. Recent MRI studies have also shown a positive correlation between the presence of high-risk features (LRNC, IPH and CAP) and an increasing degree of stenosis, maximum wall thickness or plaque burden. Our study confirms the persistence of an association between severity of carotid atherosclerosis and plaque vulnerability in a cohort of patients compliant with secondary prevention measures.

Carotid laterality as an additional element of risk. Previous studies showed that extracranial carotid-artery disease is responsible for up to 20% of strokes and that one-third of patients with cryptogenic stroke have ipsilateral non-stenotic or mildly stenotic carotid plaques.

We found no difference in maximum stenosis or atherosclerotic burden between the right and the left carotid artery. However, we observed a higher incidence of high-risk plaque features (LRNC, CAP and IPH) on the left side, as also confirmed with multiple regression analysis. To the best of our knowledge, this is the first study reporting differences in plaque composition between the right and left carotid. This finding could explain the higher rate of ischemic stroke in the left cerebral hemisphere, as shown in previous studies. Side-related differences in plaque composition could be due to a different shear stress between left and right side. Indeed, there is evidence that low shear stress causes endothelial cell dysfunction, increases lipoproteins uptake and stimulates plaque development. No study so far has demonstrated differences in shear stress between the carotid sides. However, it is known that shear stress varies inversely with vessel diameter and in the present study the left carotid artery showed a higher maximum lumen area (p < 0.01) compared to the right carotid. Accordingly, localized reduction of shear stress might influence the observed side differences in plaque composition.

Limits of the study. Due to its cross-sectional nature, this study cannot assert that lack of association between plaque vulnerability and modifiable risk factors is the effect of treatment of risk factors themselves, albeit such an effect is biologically plausible. Moreover, we did not record at the enrollment how long patients have been receiving treatment on atherosclerosis. This information could be helpful for a better understanding of the impact of medical therapy and a healthier lifestyle on plaque vulnerability and should be tested in a prospective study.

A surplus of men was not intentional but the result of referral population composition. Generalization of the results of the study must consider this datum. This is a single center study. Its findings need to be confirmed by other researches.

Conclusion. In patients with asymptomatic carotid atherosclerosis receiving evidence-based medical treatments, quantification of plaque components with high-resolution MRI demonstrates a blunted role of well-controlled modifiable RF (hypercholesterolemia, hypertension, diabetes, smoke) on the determination of a vulnerable plaque composition. Despite treatment, maximum lumen stenosis seems to be the most important independent predictor of plaque vulnerability.

Methods
Study design. The MAGNETIC study is a single center prospective observational study: it includes subjects with ultrasound evidence of carotid atherosclerosis, consecutively evaluated in a cardiovascular rehabilitation facility. The study was completed in 2019. Its primary endpoint is the reversibility of plaque vulnerability. The research is designed to detect, with a equal to 5% and power equal to 80%, a regression from a vulnerable state in 30% of subjects defined at high risk at the study start. The study design, criteria defining plaque vulnerability and
additional information about sample size calculation, are provided as supplementary material (Supplementary Fig. S1, Supplementary Table S1, Supplementary File 1).

The Ethical Committee of Istituti Clinici Scientifici Maugeri (Pavia, Italy) approved the study and all patients gave informed consent to participate in it. All methods were carried out in accordance with relevant guidelines and regulations.

Inclusion criteria were: age > 45 years; echographic evidence of 30–70% carotid stenosis, or more severe stenosis in cases of refused or contraindicated surgery. Exclusion criteria were: prior cerebral ischemia or carotid intervention (endarterectomy or stenting); contraindications for high-field MRI, claustrophobia or dementia; estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m²; allergic diathesis to gadolinium or any excipients of the contrast media; pregnancy or breast-feeding; participating in another study; any life-threatening disease with a life expectancy of less than 1 year.

The baseline cross-sectional phase of the study (completed in September 2016), included medical examination, ECG, carotid MRI and blood chemistry (high sensitive C-reactive protein, LDL cholesterol, HDL cholesterol, triglycerides, glycosylated hemoglobin, urea and creatinine), obtained on the same day. Clinical evaluation included a neurologic assessment. Patients were excluded from the study if they had a history of previous symptomatic cerebral ischemia or National Institutes of Health Stroke Scale (NIHSS) score greater than 2. Anthropometric data, atherosclerotic RF profile (according to the current European Society of Cardiology guidelines), documented history of coronary artery disease (CAD) or peripheral arterial disease (PAD) and pharmacological therapy were also recorded.

Ultrasound imaging. The maximum vessel diameter stenosis (peak stenosis) along the common/internal carotid artery (CCA, ICA) was calculated by senior vascular specialists using an up-to-date scanner (MyLab ClassC, Esaote S.p.A.), in accordance to the European Carotid Surgery Trial (ECST) method.

MRI protocol. Baseline carotid MRI was performed on a 3.0 T MRI scanner (Discovery MR750, GE Healthcare) with a bilateral six channels phased-array surface coil. Carotid bifurcations were identified by means of 3D time-of-flight (TOF) MR angiography. Thereafter, carotid bifurcations were imaged with the following MRI sequences: 2D T1-weighted, PD-weighted, and T2-weighted black-blood images and 3D TOF bright-blood angiography (FOV 16 cm, matrix size 256 × 256, in-plane resolution 0.62 × 0.62 mm, 2 signal-intensity averages). T1-weighted sequence was repeated 5 min after the administration of gadolinium contrast (Gadobutrol 1.0 mmol/ml, 0.1 mmol/kg—Bayer AG, Leverkusen). Sixteen 2-mm thick contiguous sections perpendicular or quasi-perpendicular (max tolerance: 15°) to CCA/ICA long axis were acquired. Total coverage was 32 mm around the carotid bifurcation. No adverse events occurred with injection of contrast medium.

Images analysis. Images with a quality score greater than 2, on a 5-point scale from poor to optimal (mark from 1 to 5) were post-processed. Quality score was an average value between a mark assigned at the scanning time by an experienced radiologist, based on image contrast-to-noise ratio and artifacts, and a score assigned at post-processing time, by a cardiologist with a specific training in the use of post-processing software, mainly relying on the amount of manual correction needed to draw wall and lumen contour. A validated software...
(MRI-Plaque View, VP Diagnostic, Seattle)\textsuperscript{8,17–21}, was used to analyze carotid wall composition, through semi-automatic slice-to-slice contouring of internal and external vessel borders (CCA and ICA), and multisurface signal comparison (an example of color-coded processed images is shown in Fig. 2). Metrics of carotid atherosclerosis were: peak stenosis along the CCA or the ICA (ESCT method); atherosclerotic burden, intended as the average normalized wall index (NWI = wall area/total vessel area × 100%); and LRNC, CAP and IPH percentage of the wall volume (CCA plus ICA).

**Statistics.** SPSS 17.0 software was used. Categorical variables were expressed as counts and percentage, continuous variables as median and interquartile range. Univariate associations were tested with Spearman’s ρ coefficient. Two-sided tests and a significance level < 0.05 were used for hypothesis testing. Alternatively, was used to assess independent association between plaque components and cohort’s baseline characteristics. Two-sided tests and a significance level < 0.05 were used for hypothesis testing.

Received: 4 July 2020; Accepted: 28 December 2020

Published online: 27 January 2021

**References**

1. Coombs, B. D., Rapp, J. H., Ursell, P. C., Reilly, L. M. & Saloner, D. Structure of plaque at carotid bifurcation: High-resolution MRI with histological correlation. *Stroke* **32**, 2516–2521 (2001).

2. Hatsukami, T. S., Ross, R., Polissar, N. L. & Yuan, C. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. *Circulation* **102**, 959–964 (2000).

3. Yuan, C. et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intra-plaque hemorrhage in advanced human carotid plaques. *Circulation* **104**, 2051–2056 (2001).

4. Mitsumori, L. M. et al. In vivo accuracy of multispectrum MR imaging for identifying unstable fibrous caps in advanced human carotid plaques. *J. Magn. Reson. Imaging* **17**, 410–420 (2003).

5. Chu, B. et al. Hemorrhage in the atherosclerotic carotid plaque: A high-resolution MRI study. *Stroke* **35**, 1079–1084 (2004).

6. Trivedi, R. A. et al. MRI-derived measurements of fibrous-cap and lipid-core thickness: The potential for identifying vulnerable carotid plaques in vivo. *Neuroradiology* **46**, 738–743 (2004).

7. Cai, J. et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: Comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. *Circulation* **112**, 3437–3444 (2005).

8. Saam, T. et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. *Arterioscler. Thromb. Vasc. Biol.* **25**, 234–239 (2005).

9. Xu, D. et al. Prediction of high-risk plaque development and plaque progression with the carotid atherosclerosis score. *JACC Cardiovasc. Imaging* **7**, 366–373 (2014).

10. Takaya, N. et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: A prospective assessment with MRI—Initial results. *Stroke* **37**, 818–823 (2006).

11. Alfad, N. et al. Detection of intraplaque hemorrhage by magnetic resonance imaging in symptomatic patients with mild to moderate carotid stenosis predicts recurrent neurological events. *J. Vasc. Surg.* **47**, 337–342 (2008).

12. Underhill, H. R. et al. Predictors of surface disruption with MR imaging in asymptomatic carotid artery stenosis. *AJNR Am. J. Neuroradiol.* **31**, 487–493 (2010).

13. Heijlings, W. E. et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: A prognostic study. *Circulation* **121**, 1941–1950 (2010).

14. van den Bouwhuijsen, Q. J. A. et al. Determinants of magnetic resonance imaging detected carotid plaque components: The Rotterdam Study. *Eur. Heart J.* **33**, 221–229 (2012).

15. Wasserman, B. A. et al. Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI: The multi-ethnic study of atherosclerosis (MESA). *Stroke* **39**, 329–335 (2008).

16. Virani, S. S. et al. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: The atherosclerosis risk in communities (ARIC) carotid MRI study. *Atherosclerosis* **219**, 596–602 (2011).

17. Kerwin, W. et al. Magnetic resonance imaging of carotid atherosclerosis: Plaque analysis. *Top. Magn. Reson. Imaging* **18**, 371–378 (2007).

18. Takaya, N. et al. Intravascular and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. *J. Magn. Reson. Imaging* **24**, 203–210 (2006).

19. Li, F. et al. Scan-rescan reproducibility of carotid atherosclerotic plaque morphology and tissue composition measurements using multicontrast MRI at 3T. *J. Magn. Reson. Imaging* **31**, 168–176 (2010).

20. Sun, J. et al. Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: A multicenter reproducibility study. *Int. J. Cardiovasc. Imaging* **31**, 95–103 (2015).

21. Parmar, J. P. et al. Magnetic resonance imaging of carotid atherosclerotic plaque in clinically suspected acute transient ischemic attack and acute ischemic stroke. *Circulation* **122**, 2031–2038 (2010).

22. van Lammeren, G. W. et al. Time-dependent changes in atherosclerotic plaque composition in patients undergoing carotid surgery. *Circulation* **129**, 2269–2276 (2014).

23. Abbott, A. L. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: Results of a systematic review and analysis. *Stroke* **40**, e573–e583 (2009).

24. Reeves, M. J. et al. Sex differences in stroke: Epidemiology, clinical presentation, medical care, and outcomes. *Lancet Neurol.* **7**, 915–926 (2008).

25. Wendorff, C. et al. Carotid plaque morphology is significantly associated with sex, age, and history of neurological symptoms. *Stroke* **46**, 3213–3219 (2015).

26. Sangiorgi, G. et al. Sex-related differences in carotid plaque features and inflammation. *J. Vasc. Surg.* **53**, 338–344 (2013).

27. Ota, H. et al. Sex differences in patients with asymptomatic carotid atherosclerotic plaque: In vivo 3.0-T magnetic resonance study. *Stroke* **41**, 1630–1635 (2010).

28. Schulz, U. G. R. & Rothwell, P. M. Sex differences in carotid bifurcation anatomy and the distribution of atherosclerotic plaque. *Stroke* **32**, 1525–1531 (2001).

29. Inaba, T., Chen, J. A. & Bergmann, S. R. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: A meta-analysis. *Atherosclerosis* **220**, 128–133 (2012).

30. Zhao, X. et al. Prevalence of compositional features in subclinical carotid atherosclerosis determined by high-resolution magnetic resonance imaging in Chinese patients with coronary artery disease. *Stroke* **41**, 1157–1162 (2010).
Acknowledgements
We are greatly indebted to Dr Sara Cortinovis (Bayer Italia) for her technical assistance. We acknowledge the help of Dr Daniela Cigognini (Bayer Italia), Dr Fiammetta Martini (Bayer Italia) and John H. Holmes (University of Pennsylvania) on language and editorial revision of the manuscript. We thank Dr Guido Perani for his expert advice on atherosclerosis subject.

Author contributions
O.C. designed the study, acquired and analyzed the data and drafted the manuscript. G.B. acquired the data and drafted the manuscript. A.M., M.C., M.D.S., M.F., S.M., C.P., T.A., V.T. and A.F.B. acquired the data performed the screening carotid echo. R.B., R.F.E.P., P.P. and S.G.P. gave final approval of the version to be published. Moreover, all authors contributed to the data interpretation, critically revised the manuscript and participated in the work enough to take public responsibility for the content and to agree with all aspects of the work.

Funding
This is an independent research. Although we received financial support by Bayer AG, there was not any kind of interference in any phase of the study by the pharmaceutical company.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-81247-y.

Correspondence and requests for materials should be addressed to O.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021